Difference between revisions of "Etoposide (Vepesid)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - ": new" to ": New") |
Warner-admin (talk | contribs) m (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information") |
||
| (7 intermediate revisions by 2 users not shown) | |||
| Line 4: | Line 4: | ||
<br>Extravasation: [[irritant]] | <br>Extravasation: [[irritant]] | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.<ref name="insert"></ref> |
==Diseases for which it is established ''(work in progress)''== | ==Diseases for which it is established ''(work in progress)''== | ||
| Line 13: | Line 13: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
<div style="column-count:3;-moz-column-count:3;-webkit-column-count:3"> | <div style="column-count:3;-moz-column-count:3;-webkit-column-count:3"> | ||
| + | *[[Acute lymphoblastic leukemia, infant]] | ||
*[[Acute myeloid leukemia]] | *[[Acute myeloid leukemia]] | ||
*[[Acute promyelocytic leukemia]] | *[[Acute promyelocytic leukemia]] | ||
| Line 62: | Line 63: | ||
==Patient drug information== | ==Patient drug information== | ||
*[http://packageinserts.bms.com/pi/pi_etopophos.pdf Etoposide (Vepesid) package insert]<ref name="insert"></ref> | *[http://packageinserts.bms.com/pi/pi_etopophos.pdf Etoposide (Vepesid) package insert]<ref name="insert"></ref> | ||
| − | *[https://chemocare.com/ | + | *[https://chemocare.com/druginfo/etoposide.aspx Etoposide (Vepesid) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/etoposide.aspx Etoposide (Vepesid) patient drug information (Chemocare)]</ref> |
*[http://www.uptodate.com/contents/etoposide-patient-drug-information Etoposide (Vepesid) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/etoposide-patient-drug-information Etoposide (Vepesid) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/etoposide-patient-drug-information Etoposide (Vepesid) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/etoposide-patient-drug-information Etoposide (Vepesid) patient drug information (UpToDate)]</ref> | ||
| Line 68: | Line 69: | ||
*1983-11-10: Initial FDA approval for refractory [[Testicular cancer | testicular tumors]]. ''(No supporting studies are cited)'' | *1983-11-10: Initial FDA approval for refractory [[Testicular cancer | testicular tumors]]. ''(No supporting studies are cited)'' | ||
*Uncertain date: Approed for [[small cell lung cancer]], in combination with cisplatin, as first-line treatment. ''(Based on Hainsworth et al. 1995)'' | *Uncertain date: Approed for [[small cell lung cancer]], in combination with cisplatin, as first-line treatment. ''(Based on Hainsworth et al. 1995)'' | ||
| + | ==History of changes in EMA indication== | ||
| + | *1980-07-09: EURD | ||
==History of changes in PMDA indication== | ==History of changes in PMDA indication== | ||
*2012-02-22: New additional indication and a new dosage for the treatment of [[ovarian cancer]] which has progressed after cancer chemotherapy. | *2012-02-22: New additional indication and a new dosage for the treatment of [[ovarian cancer]] which has progressed after cancer chemotherapy. | ||
| Line 73: | Line 76: | ||
==Also known as== | ==Also known as== | ||
| − | *'''Code names:''' VP-16, VP-TEC, VP 16213 | + | *'''Code names:''' VP-16, VP-TEC, VP-16213 |
*'''Generic name:''' etoposide phosphate | *'''Generic name:''' etoposide phosphate | ||
*'''Brand names:''' | *'''Brand names:''' | ||
| Line 148: | Line 151: | ||
[[Category:Irritant]] | [[Category:Irritant]] | ||
| − | [[Category:Topoisomerase inhibitors]] | + | [[Category:Topoisomerase II inhibitors]] |
| + | [[Category:Acute lymphoblastic leukemia, infant medications]] | ||
[[Category:Acute myeloid leukemia medications]] | [[Category:Acute myeloid leukemia medications]] | ||
[[Category:Acute promyelocytic leukemia medications]] | [[Category:Acute promyelocytic leukemia medications]] | ||
| Line 183: | Line 187: | ||
[[Category:Multiple myeloma medications]] | [[Category:Multiple myeloma medications]] | ||
[[Category:Neuroblastoma medications]] | [[Category:Neuroblastoma medications]] | ||
| + | [[Category:Neuroendocrine carcinoma medications]] | ||
[[Category:NK- and T-cell lymphoma medications]] | [[Category:NK- and T-cell lymphoma medications]] | ||
[[Category:Non-small cell lung cancer medications]] | [[Category:Non-small cell lung cancer medications]] | ||
| Line 199: | Line 204: | ||
[[Category:FDA approved in 1983]] | [[Category:FDA approved in 1983]] | ||
| + | [[Category:EMA approved in 1980]] | ||
[[Category:WHO Essential Cancer Medicine]] | [[Category:WHO Essential Cancer Medicine]] | ||
Latest revision as of 01:03, 29 June 2024
General information
Class/mechanism: Topoisomerase II inhibitor. Causes DNA strand breaks by interacting with DNA-topoisomerase II or by forming free radicals. Causes arrest at the G2 portion of the cell cycle, with dose dependent effects: at high concentrations, cells entering mitosis undergo lysis; at low concentrations, cells are inhibited from entering prophase.[1][2]
Route: IV, PO
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.[1]
Diseases for which it is established (work in progress)
- Non-Hodgkin lymphoma
Diseases for which it is used
- Acute lymphoblastic leukemia, infant
- Acute myeloid leukemia
- Acute promyelocytic leukemia
- Carcinoma of unknown primary
- Adrenocortical carcinoma
- Adult T-cell leukemia-lymphoma
- Anaplastic glioma
- Anaplastic large cell lymphoma
- B-cell acute lymphoblastic leukemia
- T-cell acute lymphoblastic leukemia
- Burkitt lymphoma
- Cholangiocarcinoma
- CNS lymphoma
- Diffuse large B-cell lymphoma
- Esophageal cancer
- Ewing sarcoma
- Extranodal NK- and T-cell lymphoma, nasal type
- Gallbladder cancer
- Gestational trophoblastic neoplasia
- Hemophagocytic lymphohistiocytosis
- HIV-associated lymphoma
- Classical Hodgkin lymphoma
- Hodgkin lymphoma, nodular lymphocyte-predominant
- Kaposi sarcoma
- Langerhans cell histiocytosis
- Low-grade glioma
- Mantle cell lymphoma
- Mediastinal gray-zone lymphoma
- Medulloblastoma
- Multiple myeloma
- Neuroblastoma
- NK- and T-cell lymphoma
- Non-small cell lung cancer
- Osteosarcoma
- Ovarian cancer
- Primary mediastinal B-cell lymphoma
- Rhabdomyosarcoma
- Soft tissue sarcoma
- Small cell lung cancer
- Testicular cancer
- Thymoma
- Transformed lymphoma
Patient drug information
- Etoposide (Vepesid) package insert[1]
- Etoposide (Vepesid) patient drug information (Chemocare)[3]
- Etoposide (Vepesid) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 1983-11-10: Initial FDA approval for refractory testicular tumors. (No supporting studies are cited)
- Uncertain date: Approed for small cell lung cancer, in combination with cisplatin, as first-line treatment. (Based on Hainsworth et al. 1995)
History of changes in EMA indication
- 1980-07-09: EURD
History of changes in PMDA indication
- 2012-02-22: New additional indication and a new dosage for the treatment of ovarian cancer which has progressed after cancer chemotherapy.
- 2019-03-26: New indication for the treatment prior to tumor-specific T-cell infusion therapy.
Also known as
- Code names: VP-16, VP-TEC, VP-16213
- Generic name: etoposide phosphate
- Brand names:
| Synonyms | |||||||
|---|---|---|---|---|---|---|---|
| Aside | Beposid | Bioposide | Celltop | Citodox | Epocin | Eposid | Eposide |
| Eposido | Eposin | Epsidox | ETO | Etocris | Etomedac | Etonolver | Etopofos |
| Etopophos | Etopos | Etoposid | Etoposido | Etopoxan | Etopul | Etosid | Etosin |
| Eunades CS | Euvaxon | Exitop | Fytop | Fytosid | Labimion | Lastet | Lastet S |
| Neoplaxol | Nexvep | Onkoposid | Optasid | Percas | Posid | Posidon | Posyd |
| Riboposid | Sintopozid | Toposar | Toposide | Toposin | Topresid | Tosuben | Vepefos |
| Vepesid | Vepeside | Vepsid | Vepside | ||||
References
Categories:
- Drugs
- Intravenous medications
- Oral medications
- Irritant
- Topoisomerase II inhibitors
- Acute lymphoblastic leukemia, infant medications
- Acute myeloid leukemia medications
- Acute promyelocytic leukemia medications
- Carcinoma of unknown primary medications
- Adrenocortical carcinoma medications
- Adult T-cell leukemia-lymphoma medications
- Anaplastic glioma medications
- Anaplastic large cell lymphoma medications
- B-cell acute lymphoblastic leukemia medications
- T-cell acute lymphoblastic leukemia medications
- Burkitt lymphoma medications
- Cholangiocarcinoma medications
- CNS lymphoma medications
- Diffuse large B-cell lymphoma medications
- Esophageal adenocarcinoma medications
- Esophageal cancer medications
- Esophageal squamous cell carcinoma medications
- Ewing sarcoma medications
- Extranodal NK- and T-cell lymphoma, nasal type medications
- Follicular lymphoma medications
- Gallbladder cancer medications
- Gestational trophoblastic neoplasia medications
- Hemophagocytic lymphohistiocytosis medications
- HIV-associated lymphoma medications
- Classical Hodgkin lymphoma medications
- Hodgkin lymphoma, nodular lymphocyte-predominant medications
- Langerhans cell histiocytosis medications
- Low-grade glioma medications
- Low-grade glioma, pediatric medications
- Mantle cell lymphoma medications
- Mediastinal gray-zone lymphoma medications
- Medulloblastoma medications
- Multiple myeloma medications
- Neuroblastoma medications
- Neuroendocrine carcinoma medications
- NK- and T-cell lymphoma medications
- Non-small cell lung cancer medications
- Non-small cell lung cancer, nonsquamous medications
- Osteosarcoma medications
- Ovarian cancer medications
- Peripheral T-cell lymphoma medications
- Primary mediastinal B-cell lymphoma medications
- Rhabdomyosarcoma medications
- Soft tissue sarcoma medications
- Small cell lung cancer medications
- Testicular cancer medications
- Thymoma medications
- Transformed lymphoma medications
- Kaposi sarcoma medications
- FDA approved in 1983
- EMA approved in 1980
- WHO Essential Cancer Medicine